Association Study of –1727 A/T, –50 C/T and (CAA)n Repeat GSK-3β Gene Polymorphisms with SchizophreniaScassellati C. · Bonvicini C. · Perez J. · Bocchio-Chiavetto L. · Tura G.B. · Rossi G. · Racagni G. · Gennarelli M.
aGenetic Unit, bPsychiatric Rehabilitation Center IRCCS ‘San Giovanni di Dio’, Fatebenefratelli, and cDivision of Biology and Genetics, Department of Biomedical Sciences and Biotechnologies, University of Brescia, Brescia, dCenter of Neuropharmacology, Institute of Pharmacological Sciences, University of Milan, Milan, Italy
Glycogen synthase kinase-3 (GSK-3) is a downstream component of the Wnt pathway and recent studies have reported abnormal levels of GSK-3β in schizophrenia. In a sample of 147 schizophrenic patients and 212 healthy individuals, we analyzed two common SNPs at position –1727 A/T and –50 C/T and a (CAA)n repeat polymorphism localized in intron 1 of the gene. The results showed that the allele, genotype and haplotype distributions for the three polymorphisms investigated do not differ between schizophrenic patients in general and control subjects. However, in the subtype of paranoid schizophrenic patients, we found that the (CAA)3/(CAA)5 heterozygotes were more often represented. Although taken from a small sample, our results support the reports that GSK-3β appears to be involved in a subtype of schizophrenic patients, but not in schizophrenia in general. In conclusion, we would speculate that this gene may be linked to some features of psychotic disorders rather than to schizophrenia itself.
|Direct payment||This item at the regular price: USD 38.00|
|Payment from account||With a Karger Pay-per-View account (down payment USD 150)
you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50